Acceleron Pharma Inc.
BMPRII POLYPEPTIDES AND USES THEREOF
Last updated:
Abstract:
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of bone morphogenetic protein receptor type II (BMPRII) polypeptide binds to ligands including BMP10, BMP15, activin B and BMP9 and may be used to treat fibrotic and angiogenic disorders.
Status:
Application
Type:
Utility
Filling date:
11 Feb 2020
Issue date:
7 Jan 2021